MedPath
FDA Approval

LUMOXITI

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
February 8, 2022
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Moxetumomab pasudotox(1 mg in 1 mL)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

AstraZeneca PLC

230790719

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

LUMOXITI

Product Details

NDC Product Code
0310-4700
Application Number
BLA761104
Marketing Category
BLA (C73585)
Route of Administration
INTRAVENOUS
Effective Date
February 8, 2022
Code: 2NDX4B6N8FClass: ACTIBQuantity: 1 mg in 1 mL
GLYCINEInactive
Code: TE7660XO1CClass: IACTQuantity: 80 mg in 1 mL
POLYSORBATE 80Inactive
Code: 6OZP39ZG8HClass: IACTQuantity: 0.2 mg in 1 mL
SUCROSEInactive
Code: C151H8M554Class: IACTQuantity: 40 mg in 1 mL
SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATEInactive
Code: 593YOG76RNClass: IACTQuantity: 3.4 mg in 1 mL

IV Solution Stabilizer

Product Details

NDC Product Code
0310-4715
Application Number
BLA761104
Marketing Category
BLA (C73585)
Route of Administration
INTRAVENOUS
Effective Date
February 8, 2022
Code: 6OZP39ZG8HClass: ACTIBQuantity: 6.5 mg in 1 mL
CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QPClass: IACTQuantity: 0.7 mg in 1 mL
TRISODIUM CITRATE DIHYDRATEInactive
Code: B22547B95KClass: IACTQuantity: 6.4 mg in 1 mL
WATERInactive
Code: 059QF0KO0RClass: IACTQuantity: 1.0 mg in 1 mL
© Copyright 2025. All Rights Reserved by MedPath